secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001847903-24-000052
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa reports Q4 net loss $36.8M; cash $256.5M; SerpinPC and ORX750 milestones on track
--------------------------------------------------------------------------------

- Net loss of $36.8M for Q4 2023 vs $43.2M YoY; full-year net loss $151.1M vs $216.2M.
- Cash, equivalents and ST investments $256.5M at Dec 31, 2023; plus $9.7M ATM proceeds in Jan 2024; funding into 2026.
- SerpinPC PRESent-2 Part 1 interim analysis planned in 2024; Part 1 data at medical conference late 2024/early 2025.
- ORX750 IND clearance targeted; clinical proof-of-concept data in sleep-deprived healthy volunteers expected in 2024.
- Phase 2a SerpinPC data showed 96% median all-bleed ABR reduction with no thromboembolic events to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000052/0001847903-24-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000052/cnta-20240328.htm
  HTML page:      https://secwatch.observer/filing/0001847903-24-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer